PD21-03 ARE INDUSTRY PAYMENTS FOR TADALAFIL ASSOCIATED WITH PRESCRIBING HABITS AMONG UROLOGISTS AND PRIMARY CARE PHYSICIANS?

INTRODUCTION AND OBJECTIVES:Prior studies have shown that pharmaceutical industry payments may be associated with prescribing habits among physicians. The relationship between payments and prescription of phosphodiesterase type 5 inhibitors (PDE5i) has not been explored. In this study, we evaluated whether industry payments for tadalafil were associated with prescribing habits among urologists (URO) and primary care physicians (PCPs).METHODS:Medicare Part D Public Use File and Open Payments Program database (OPP) were linked to identify URO and PCPs who prescribed and received a payment for tadalafil in 2015. PCPs were defined as internal medicine and family medicine physicians. We determined whether presence of and extent of payment were associated with prescription of tadalafil as well as the number of claims. Statistical tests included chi-squared test, univariable logistic regression and Pearson correlation coefficient.RESULTS:Within Medicare Part D, 2,602 URO and 3,095 PCPs prescribed tadalafil. With...